Clinical trial NCT01239914: CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
Official title: CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Drug Eluting Stent
Coronary Artery Disease
Polymorphism
Cholesterol
Biomarker
Keywords: drug eluting stent
coronary artery disease
Korean registry
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
Collaborators: name: Seoul St. Mary's Hospital
name: Yeouido St. Mary's Hospital
name: Bucheon St. Mary's Hospital
name: St.Paul's Hospital, Korea
name: Incheon St.Mary's Hospital
name: Saint Vincent's Hospital, Korea
name: Daejeon St. Mary's hospital
First posted: 2010-11-15
Enrollment: 11719
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all comers who admitted cardiovascular center for coronary stent implantation

Brief summary: COACT registry is a multicenter registry of consecutive patients undergoing coronary stent implantation at 8 centers in the Catholic University of Korea to evaluate the real world management of patients with coronary artery disease and to assess their in-hospital, medium and long-term outcomes.


Eligibility criteria: Inclusion Criteria:

* all consecutive patients who underwent percutaneous coronary intervention
* written informed consent for the DNA and serum databank

Exclusion Criteria:

* patients who did not agreed to participate

Primary outcomes:
measure: All causes mortality
timeFrame: 6month, each year
measure: Cardiac death
timeFrame: 6 month, each year
measure: Myocardial infarction
timeFrame: 6 month, each year
measure: target lesion revascularization
timeFrame: 6 month, each year
measure: target vessel revascularization
timeFrame: 6 month, each year
Secondary outcomes:
measure: non target vessel revascularization
timeFrame: 6 month, each year
measure: Stent thrombosis
timeFrame: 6 month, each year
measure: Serum databank for evaluation of biomarkers outcomes
timeFrame: 6 month, each year
measure: Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes
timeFrame: 6 month, each year
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: Bucheon St.Mary Hospital
state: Gyeonggido
city: Suwon
country: Korea, Republic of
facility: St.Vincent's Hospital
state: Gyeonggido
city: Uijeongbu
country: Korea, Republic of
facility: Uijeongbu St.Mary's Hospital
state: Gyeonggido
city: Daejeon
country: Korea, Republic of
facility: Daejeon St.Mary's Hospital
city: Incheon
country: Korea, Republic of
facility: Incheon St.Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul St.Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: St.Paul's Hospital
city: Seoul
country: Korea, Republic of
facility: Yeouido St.Mary Hospital
Study officials:
affiliation: Seoul St. Mary's Hospital
name: Ki-Bae Seung, M.D.,PhD
role: STUDY_CHAIR
References:
citation: Kim HS, Chang K, Koh YS, Park MW, Choi YS, Park CS, Oh M, Kim EY, Shon JH, Shin JG, Seung KB. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Circ Cardiovasc Genet. 2013 Oct;6(5):514-21. doi: 10.1161/CIRCGENETICS.113.000109. Epub 2013 Sep 9.